JP2016530291A5 - - Google Patents
Download PDFInfo
- Publication number
- JP2016530291A5 JP2016530291A5 JP2016539645A JP2016539645A JP2016530291A5 JP 2016530291 A5 JP2016530291 A5 JP 2016530291A5 JP 2016539645 A JP2016539645 A JP 2016539645A JP 2016539645 A JP2016539645 A JP 2016539645A JP 2016530291 A5 JP2016530291 A5 JP 2016530291A5
- Authority
- JP
- Japan
- Prior art keywords
- metadoxine
- composition
- sustained release
- disorder
- administered
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Pending
Links
- RYKKQQUKJJGFMN-HVDRVSQOSA-N 4,5-bis(hydroxymethyl)-2-methylpyridin-3-ol;(2S)-5-oxopyrrolidine-2-carboxylic acid Chemical compound OC(=O)[C@@H]1CCC(=O)N1.CC1=NC=C(CO)C(CO)=C1O RYKKQQUKJJGFMN-HVDRVSQOSA-N 0.000 claims 11
- 239000000203 mixture Substances 0.000 claims 10
- 230000002459 sustained Effects 0.000 claims 6
- 201000010099 disease Diseases 0.000 claims 2
- 206010000117 Abnormal behaviour Diseases 0.000 claims 1
- 208000001914 Fragile X Syndrome Diseases 0.000 claims 1
- 108009000484 Fragile X Syndrome Proteins 0.000 claims 1
- 206010024094 Learning disease Diseases 0.000 claims 1
- 201000007185 autism spectrum disease Diseases 0.000 claims 1
- 239000002552 dosage form Substances 0.000 claims 1
- 201000003723 learning disability Diseases 0.000 claims 1
- 239000006186 oral dosage form Substances 0.000 claims 1
- 230000011273 social behavior Effects 0.000 claims 1
- 230000003442 weekly Effects 0.000 claims 1
Claims (9)
(b)徐放メタドキシンと即時放出メタドキシンの相対比が約60:40〜80:20の間である、
請求項5に記載の組成物。 (A) the sustained release form provides a sustained release of said metadoxine for at least 8 hours; and
(B) the relative ratio of sustained release metadoxine and immediate release metadoxine is between about 60:40 and 80:20;
The composition according to claim 5.
Applications Claiming Priority (7)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
US201361875384P | 2013-09-09 | 2013-09-09 | |
US61/875,384 | 2013-09-09 | ||
US14/038,258 US20150073023A1 (en) | 2013-09-09 | 2013-09-26 | Method Of Treating Fragile X Syndrome And Related Disorders |
US14/038,258 | 2013-09-26 | ||
US201461991351P | 2014-05-09 | 2014-05-09 | |
US61/991,351 | 2014-05-09 | ||
PCT/IB2014/002398 WO2015033224A2 (en) | 2013-09-09 | 2014-09-09 | Methods of treating fragile x syndrome and related disorders |
Publications (2)
Publication Number | Publication Date |
---|---|
JP2016530291A JP2016530291A (en) | 2016-09-29 |
JP2016530291A5 true JP2016530291A5 (en) | 2017-10-19 |
Family
ID=52629036
Family Applications (2)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
JP2016540930A Pending JP2016530536A (en) | 2013-09-09 | 2014-09-09 | Of determining response to therapy |
JP2016539645A Pending JP2016530291A (en) | 2013-09-09 | 2014-09-09 | Method for treating fragile X syndrome and related disorders |
Family Applications Before (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
JP2016540930A Pending JP2016530536A (en) | 2013-09-09 | 2014-09-09 | Of determining response to therapy |
Country Status (12)
Country | Link |
---|---|
EP (2) | EP3044589A1 (en) |
JP (2) | JP2016530536A (en) |
KR (2) | KR20160086818A (en) |
CN (2) | CN105517546A (en) |
AU (2) | AU2014316779A1 (en) |
CA (2) | CA2922901A1 (en) |
EA (2) | EA201690559A1 (en) |
IL (2) | IL244343A0 (en) |
MX (2) | MX2016003006A (en) |
SG (2) | SG11201601830PA (en) |
TW (2) | TW201605443A (en) |
WO (2) | WO2015035402A1 (en) |
Families Citing this family (8)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
CN105431442B (en) * | 2013-07-31 | 2018-08-07 | Udc 爱尔兰有限责任公司 | Luminous diaza benzo imidazole carbene metal complex |
US20150073023A1 (en) | 2013-09-09 | 2015-03-12 | Alcobra Ltd. | Method Of Treating Fragile X Syndrome And Related Disorders |
CN108538365A (en) * | 2017-03-24 | 2018-09-14 | 华东师范大学 | A kind of self-closing disease sociability assessment system based on data analysis technique |
US10864182B2 (en) * | 2018-04-13 | 2020-12-15 | Healx Limited | Treatment of fragile X syndrome |
KR20190121569A (en) * | 2018-04-18 | 2019-10-28 | 건국대학교 글로컬산학협력단 | Pharmaceutical Composition for Improving Fragile X Syndrome Comprising Agmatine or its derivatives |
IL304270B1 (en) * | 2018-06-07 | 2024-06-01 | Ovid Therapeutics Inc | Use of (s)-3-amino-4-(difluoromethylenyl) cyclopent-1-ene-1-carboxylic acid and related compounds, (1s,3s)-3-amino-4-(difluoromethylidene) cyclopentane-1-carboxylic acid and vigabatrin in the treatment of developmental disorders |
JP7490064B2 (en) * | 2020-01-08 | 2024-05-24 | ニューロヴェンティ カンパニー リミテッド | Composition for treating fragile X syndrome or related developmental disorders containing Lislead compound as an active ingredient |
EP4101448A4 (en) * | 2020-02-07 | 2024-04-24 | Neuroventi | Composition comprising rilmenidine compound as active ingredient for treatment of fragile x syndrome or related developmental disability |
Family Cites Families (4)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
IT1131856B (en) | 1980-06-30 | 1986-06-25 | Baldacci Lab Spa | PHARMACEUTICAL COMPOSITION FOR THE TREATMENT OF ALCOHOLIC INTOXICATIONS |
US20020155170A1 (en) * | 2000-11-30 | 2002-10-24 | Walsh William John | Nutrient supplements and methods for treating autism and for preventing the onset of autism |
IL187159A0 (en) | 2007-07-03 | 2009-02-11 | Gur Megiddo | Use of metadoxine in relief of alcohol intoxication |
NZ597319A (en) * | 2009-06-25 | 2014-06-27 | Alcobra Ltd | A method for the treatment, alleviation of symptoms of, relieving, improving and preventing a cognitive disease, disorder or condition |
-
2014
- 2014-09-05 TW TW103130856A patent/TW201605443A/en unknown
- 2014-09-05 TW TW103130859A patent/TW201606304A/en unknown
- 2014-09-09 CA CA2922901A patent/CA2922901A1/en not_active Abandoned
- 2014-09-09 AU AU2014316779A patent/AU2014316779A1/en not_active Abandoned
- 2014-09-09 WO PCT/US2014/054816 patent/WO2015035402A1/en active Application Filing
- 2014-09-09 KR KR1020167009042A patent/KR20160086818A/en not_active Application Discontinuation
- 2014-09-09 JP JP2016540930A patent/JP2016530536A/en active Pending
- 2014-09-09 KR KR1020167009040A patent/KR20160078956A/en not_active Application Discontinuation
- 2014-09-09 AU AU2014315026A patent/AU2014315026A1/en not_active Abandoned
- 2014-09-09 WO PCT/IB2014/002398 patent/WO2015033224A2/en active Application Filing
- 2014-09-09 MX MX2016003006A patent/MX2016003006A/en unknown
- 2014-09-09 JP JP2016539645A patent/JP2016530291A/en active Pending
- 2014-09-09 MX MX2016003002A patent/MX2016003002A/en unknown
- 2014-09-09 EP EP14776939.2A patent/EP3044589A1/en not_active Withdrawn
- 2014-09-09 CN CN201480049671.5A patent/CN105517546A/en active Pending
- 2014-09-09 EP EP14830858.8A patent/EP3043792A2/en not_active Withdrawn
- 2014-09-09 EA EA201690559A patent/EA201690559A1/en unknown
- 2014-09-09 CN CN201480060722.4A patent/CN105917225A/en active Pending
- 2014-09-09 EA EA201690557A patent/EA201690557A1/en unknown
- 2014-09-09 CA CA2923421A patent/CA2923421A1/en not_active Abandoned
- 2014-09-09 SG SG11201601830PA patent/SG11201601830PA/en unknown
- 2014-09-09 SG SG11201601605YA patent/SG11201601605YA/en unknown
-
2016
- 2016-02-29 IL IL244343A patent/IL244343A0/en unknown
- 2016-03-06 IL IL244453A patent/IL244453A0/en unknown
Similar Documents
Publication | Publication Date | Title |
---|---|---|
JP2016530291A5 (en) | ||
HRP20210819T1 (en) | Fenfluramine for use in the treatment of dravet syndrome | |
JP2018193377A5 (en) | ||
JP2012193216A5 (en) | ||
EA201690107A1 (en) | PHARMACEUTICAL COMPOSITION CONTAINING DIMETHYLFUMATE FOR INTRODUCTION TO LOW DAILY DOSE | |
JP2010248252A5 (en) | ||
MY181159A (en) | Sublingual and buccal film compositions | |
JP2015057451A5 (en) | ||
UY35624A (en) | USE OF HIGH DOSE PRIDOPIDINE TO TREAT HUNTINGTON'S DISEASE | |
JP2014111603A5 (en) | ||
JP2016147915A5 (en) | ||
JP2010285439A5 (en) | ||
BR112015018168A2 (en) | soft rock inhibitors | |
JP2015517488A5 (en) | ||
JP2013505205A5 (en) | ||
JP2013231087A5 (en) | ||
RU2017116740A (en) | COMBINATIONS FOR THE TREATMENT OF MULTIPLE SCLEROSIS | |
JP2015525757A5 (en) | ||
MX340985B (en) | N-heteroaryl compounds. | |
AR091351A1 (en) | BROMOCRIPTINE FORMULATIONS, METHOD FOR IMPROVING GLUCEMIC CONTROL AND METHOD FOR MANUFACTURING | |
MX340188B (en) | Manufacturing of active-free granules and tablets comprising the same. | |
JP2013541583A5 (en) | ||
BR112014014795A2 (en) | immediate release multi-unit pellet system | |
JP2014507475A5 (en) | ||
JP2012516348A5 (en) |